


IMPACT  
FACTOR  
4.433




Journal of  
*Personalized  
Medicine*

an Open Access Journal by MDPI



Academic Open Access Publishing  
since 1996



an Open Access Journal by MDPI







#### Editor-in-Chief

Prof. Dr. Stephen B. Liggett

#### Message from the Editor-in-Chief

*Journal of Personalized Medicine* is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

#### Author Benefits

-  **Open Access** Unlimited and free access for readers
-  **No Copyright Constraints** Retain copyright of your work and free use of your article
-  **Coverage by Leading Indexing Services** SCIE-Science Citation Index Expanded (Clarivate Analytics), PubMed (NLM), PubMed Central(NLM), Scopus (Elsevier)
-  **Thorough Peer-Review**
-  **Rapid Publication** Accepted papers are immediately published online
-  **No Space Constraints, No Extra Space or Color Charges** No restriction on the length of the papers, number of figures or colors

## Aims and Scope

For a comprehensive perspective of primary research, commentaries, and reviews related to personalized medicine, also termed precision medicine, *JPM* aims to integrate expertise from the molecular and translational sciences, therapeutics and diagnostics, as well as discussions of regulatory, social, ethical and policy aspects.

Topics of interest with a view towards personalized medicine:

- Omics-based studies of disease risk, disease prognosis, and response to therapy
- Biomarker identification and application
- Drug target discovery and integration with individualized therapy
- Pharmacogenomics – genetics and biochemistry of drug uptake, action, and metabolism
- Prediction-based drug safety
- Novel therapeutics: genetic-based, nanotechnology, targeting strategies
- Advancements in Technologies and Resources (genetic testing, expression analysis, microbiomes, genome-wide association studies, bioinformatics and health informatics, biostatistics)
- Personalization of omics-based non-drug related health interventions
- Regulation and bioethics in personalized medicine

### Editorial Office

*JPM* Editorial Office  
jpm@mdpi.com  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
Fax: +41 61 302 89 18  
www.mdpi.com  
mdpi.com/journal/jpm

## MDPI is a member of




## Follow Us

 [facebook.com/MDPIOpenAccessPublishing](https://facebook.com/MDPIOpenAccessPublishing)

 [twitter.com/MDPIOpenAccess](https://twitter.com/MDPIOpenAccess)

 [linkedin.com/company/mdpi](https://linkedin.com/company/mdpi)

 [weibo.com/mdpicn](https://weibo.com/mdpicn)

 Wechat: MDPI-China

 [blog.mdpi.com](https://blog.mdpi.com)



[www.mdpi.com](https://www.mdpi.com)

[mdpi.com/journal/jpm](https://mdpi.com/journal/jpm)

See [www.mdpi.com](https://www.mdpi.com) for a full list of offices and contact information. MDPI is a company registered in Basel, Switzerland, No. CH-270.3.014.334-3, whose registered office is at St. Alban-Anlage 66, CH-4052 Basel, Switzerland.

Basel, January 2021